Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Artivion’s FDA updates, clinical-trial costs, and global device revenues can feel overwhelming when each SEC report stretches well past 200 pages. Whether you are tracking new aortic stent graft approvals or trying to spot shifts in mechanical heart-valve demand, the technical language in an Artivion annual report 10-K or a fresh 10-Q quarterly earnings report often masks the insights that drive decisions.
Stock Titan solves this problem. Our AI engine turns every filing into plain-English takeaways—Artivion SEC filings explained simply. Get instant alerts the moment an Artivion 8-K material event lands on EDGAR, skim AI-generated risk highlights, or drill straight into segment revenue tables without sifting through footnotes. Need to monitor management’s sentiment? Real-time dashboards surface Artivion Form 4 insider transactions so you can gauge executive conviction ahead of pivotal FDA milestones.
The platform covers every document type investors ask about:
- 10-K sections on product liability and clinical data—already summarized and compared year-over-year.
- 10-Q snapshots for revenue growth by valve, graft, and adhesive lines—ideal for quick Artivion earnings report filing analysis.
- 8-K event briefs that explain recall notices or trial results in minutes.
- Proxy statements outlining Artivion executive compensation and option grants.
- Form 4 dashboards showing Artivion insider trading Form 4 transactions in real time.
Artivion, Inc.'s Chief Commercial Officer reported selling company stock in an insider transaction. On 12/15/2025, John E. Davis sold 5,000 shares of Artivion common stock at $45.11 per share, as reflected in a regulatory report.
After this sale, Davis beneficially owned 193,842 Artivion shares, all held directly. The report was filed by him as a single reporting person in his role as Chief Commercial Officer.
John E. Davis submitted a notice of proposed sale of 5000 shares of the issuer’s common stock through broker Charles Schwab, with an approximate sale date of 12/15/2025. The shares have an aggregate market value of 225553.67 as reported in the notice and are listed on the NYSE.
The notice states that 47374939 common shares were outstanding, which helps put the planned sale in context. Davis originally acquired 10000 common shares from the issuer in a purchase on 09/16/2020, with payment made on the same date. By signing, the seller represents that he is not aware of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Artivion, Inc. insider Form 4 details a routine tax-related stock sale. The company’s Vice President and Chief Accounting Officer reported selling 4,572 shares of Artivion common stock on 12/08/2025 at a price of $44.419 per share. After this transaction, the officer beneficially owned 130,058 shares directly.
The filing explains that the shares were sold automatically upon the vesting of restricted stock units to cover tax withholding obligations through a “sell to cover” transaction, meaning it was not a discretionary open-market trade by the insider.
An AORT shareholder filed a Rule 144 notice to sell up to 4,572 shares of common stock through Fidelity Brokerage Services on the NYSE around 12/08/2025. The filing lists an aggregate market value of $203,081.38 for this planned sale, compared with 47,374,939 common shares outstanding for the issuer. The seller acquired these 4,572 shares as restricted stock vesting from the issuer on 12/05/2025, treated as compensation.
Over the prior three months, the same seller reported additional open-market sales of the issuer’s common stock: 1,789 shares on 11/10/2025 for $79,823.21, 3,482 shares on 11/13/2025 for $159,678.60, and 6,000 shares on 11/17/2025 for $274,382.11. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Artivion, Inc. reported an insider stock transaction by its President & CEO, James P. Mackin. On December 3, 2025, he exercised stock options to acquire 30,921 shares of Artivion common stock at an exercise price of $29.62 per share, then sold the same 30,921 shares in the open market at a weighted average price of approximately $45.461 per share.
The option exercise and sale were conducted under a Rule 10b5-1 trading plan adopted on September 2, 2025. After these transactions, he directly owns 800,993 shares of Artivion common stock. The reported stock option, originally granted on March 5, 2020 with an expiration date of March 5, 2026, is now fully exercised and shows 0 options remaining.
Artivion, Inc. executive Jean F. Holloway, the company’s SVP and General Counsel, reported open-market sales of company stock. On 12/03/2025, she sold 2,048 shares of Artivion common stock at a price of $45.3 per share and, in a separate transaction the same day, sold an additional 5,267 shares at $45.3 per share.
Following these transactions, Holloway beneficially owns 156,093 shares of Artivion common stock directly. The filing is a standard Form 4 disclosure of insider trading activity required for company officers.
Artivion, Inc. (AORT) reported an insider stock transaction by its President & CEO. On 12/02/2025, the executive exercised stock options to buy 30,921 shares of common stock at an exercise price of $29.62 per share and then sold 30,921 shares of common stock in a separate transaction at a weighted average price of $45.559 per share.
The transactions were executed under a Rule 10b5-1 trading plan adopted on September 2, 2025. Following these moves, the reporting person held 800,993 shares of Artivion common stock in direct ownership.
James Mackin filed a Form 144 notice to sell 30,921 common shares of the issuer through Fidelity Brokerage Services LLC on the NYSE, with 47,374,939 shares outstanding. The shares relate to an option originally granted on 03/05/2019 and acquired on 12/03/2025, with the purchase price paid in cash on the same date. In the past three months, Mackin has sold additional common shares in three transactions, totaling 17,580 shares for gross proceeds of $784,400.26, 34,210 shares for $1,568,812.44, and 30,921 shares for $1,408,736.02. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.
An insider of the issuer has filed a Form 144 notice to sell 7,315 shares of common stock through broker Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an aggregate market value of $331,390.71, while 47,374,939 shares of this class were outstanding at the time of the notice. The shares to be sold were acquired as restricted stock from the issuer on 02/22/2019 and 02/21/2020.
Over the past three months, the same seller, Jean F. Holloway, has already sold several blocks of common stock, including 10,000 shares on 11/11/2025 for gross proceeds of $461,800.00. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Artivion, Inc. executive reports charitable stock gift
An officer of Artivion, Inc., serving as VP and Chief Accounting Officer, filed a Form 4 reporting a gift of 750 shares of Artivion common stock on 12/01/2025. The transaction is coded as a gift and priced at $0, reflecting that the shares were donated rather than sold. After this transaction, the reporting person directly owns 134,630 shares of Artivion common stock. The explanation clarifies that the 750 shares were gifted to a charity.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
